Ruby Biopharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.15 M
- Company Age 17 Year, 18 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 11.40 Cr
- Revenue Growth 2.26%
- Profit Growth 74.06%
- Ebitda 74.89%
- Net Worth 21.32%
- Total Assets 14.88%
About Ruby Biopharma
Ruby Biopharma Private Limited (RBPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 21 January 2008 and has a history of 17 years. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.15 M.
The company currently has active open charges totaling ₹11.40 Cr.
Rumy Kumar and Ruby Kumar serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24234MH2008PTC178070
-
Company No.
178070
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Jan 2008
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Ruby Biopharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rumy Kumar
|
Director | 21-Jan-2008 | Current |
|
Ruby Kumar
|
Director | 21-Jan-2008 | Current |
Financial Performance of Ruby Biopharma.
Ruby Biopharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.26% increase. The company also saw a substantial improvement in profitability, with a 74.06% increase in profit. The company's net worth Soared by an impressive increase of 21.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ruby Biopharma?
In 2023, Ruby Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Viilbery Healthcare Private LimitedRumy Kumar is a mutual person
-
Ruby Organics Private LimitedRumy Kumar and Ruby Kumar are mutual person
-
Ruby Bio-Tech Private Limited
Rumy Kumar is a mutual person
Charges (Loans)
₹114.00 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 11.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Mar 2024 | Axis Bank Limited | ₹6.00 Cr | Open |
| 04 Mar 2024 | Axis Bank Limited | ₹5.40 Cr | Open |
How Many Employees Work at Ruby Biopharma?
Ruby Biopharma has a workforce of 3 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ruby Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ruby Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
